PTC Therapeutics, Inc. (PTCT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 37.20 |
| Open | 37.76 |
| Bid | 36.42 x 300 |
| Ask | 36.50 x 100 |
| Day's range | 36.25 - 37.76 |
| 52-week range | 17.53 - 45.68 |
| Volume | |
| Avg. volume | 906,204 |
| Market cap | 2.797B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.54 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.64 |
PR NewswirePTC Therapeutics Announces Validation of Sepiapterin European MAA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.
GuruFocus.comInsider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT)
Director Jerome Zeldis of PTC Therapeutics Inc (NASDAQ:PTCT) executed a sale of 20,000 shares of the company on May 22, 2024, according to a recent SEC Filing.
ZacksThe Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
© 2024 Yahoo. All rights reserved.